Turning stats into outcomes
July 18, 2012
US drugmakers have been taken aback by an appeal court's decision this week that "pay-for-delay" deals aimed at keeping generic competition off the market are anti-competitive.
May 18, 2012
The US market for Sanofi/Bristol-Myers Squibb's Plavix has been blown wide open after regulators across the Atlantic gave the green light to copycat versions of the companies' mega-blockbuster bloodthinner
March 27, 2012
Hours after AstraZeneca failed in its latest bid to prevent generics of Seroquel from entering the market, Teva Pharmaceuticals Industries has already launched copycat versions of the antipsychotic blockbuster
February 23, 2012
If Australia had paid English prices for generic simvastatin during May 2010-October 2011, its PBS spending could have been reduced from $150 million to just A$20 million, says a leading health economist.
PharmaTimes 2013 Copyright | RSS Feed Subscriptions